SV2009003238A - Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada - Google Patents

Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada

Info

Publication number
SV2009003238A
SV2009003238A SV2009003238A SV2009003238A SV2009003238A SV 2009003238 A SV2009003238 A SV 2009003238A SV 2009003238 A SV2009003238 A SV 2009003238A SV 2009003238 A SV2009003238 A SV 2009003238A SV 2009003238 A SV2009003238 A SV 2009003238A
Authority
SV
El Salvador
Prior art keywords
dosage forms
chlorhydrate
palonosetron
improved stability
biodisponibility
Prior art date
Application number
SV2009003238A
Other languages
English (en)
Inventor
Daniele Bonadeo
Giorgio Calderari
Enrico Braglia
Ricardo Braglia
Original Assignee
Helsinn Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2009003238(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Helsinn Healthcare Sa filed Critical Helsinn Healthcare Sa
Publication of SV2009003238A publication Critical patent/SV2009003238A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A61K9/5057—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Abstract

SIEMPRE QUE SEAN FORMAS DE DOSIFICACIÓN ORALES SÓLIDAS DEL CLORHIDRATO DE PALONOSETRON, LOS MÉTODOS PARA USAR LAS FORMAS DE DOSIFICACIÓN PARA TRATAR EL VOMITO, Y LOS MÉTODOS PARA HACER LOS FORMAS DE DOSIFICACIÓN. LOS FORMAS DE DOSIFICACIÓN HAN MEJORADO LA ESTABILIDAD Y BIODISPONIBILIDAD, Y ESTAN PREFERIBLEMENTE BAJO LA FORMA DE CAPSULAS RELLENAS DE LIQUIDO
SV2009003238A 2006-10-24 2009-04-24 Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada SV2009003238A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24

Publications (1)

Publication Number Publication Date
SV2009003238A true SV2009003238A (es) 2009-11-09

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003238A SV2009003238A (es) 2006-10-24 2009-04-24 Formas de dosificacion del clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada

Country Status (36)

Country Link
US (2) US20080152704A1 (es)
EP (1) EP1940366B9 (es)
JP (1) JP5144527B2 (es)
KR (1) KR101441459B1 (es)
CN (1) CN101573106B (es)
AR (1) AR063362A1 (es)
AT (1) ATE427742T1 (es)
AU (1) AU2007308378B2 (es)
BR (1) BRPI0718497B1 (es)
CA (1) CA2666512C (es)
CL (1) CL2007003055A1 (es)
CO (1) CO6160289A2 (es)
CR (1) CR10728A (es)
CY (1) CY1109914T1 (es)
DE (1) DE602007000856D1 (es)
DK (1) DK1940366T3 (es)
EA (1) EA016455B1 (es)
ES (1) ES2325339T3 (es)
GT (1) GT200900096A (es)
HK (1) HK1117769A1 (es)
HN (1) HN2009000785A (es)
HR (1) HRP20090341T1 (es)
IL (1) IL198225A (es)
ME (1) ME01949B (es)
MX (1) MX2009004461A (es)
NO (1) NO342353B1 (es)
NZ (1) NZ576237A (es)
PL (1) PL1940366T3 (es)
PT (1) PT1940366E (es)
RS (1) RS50842B (es)
SI (1) SI1940366T1 (es)
SV (1) SV2009003238A (es)
TW (1) TWI367212B (es)
UA (1) UA97653C2 (es)
WO (1) WO2008049552A1 (es)
ZA (1) ZA200902773B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640460C (en) * 2006-01-27 2015-05-26 Eurand, Inc Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
CA2640382C (en) * 2006-01-27 2015-12-29 Eurand, Inc Drug delivery systems comprising weakly basic drugs and organic acids
EP2364138A2 (en) 2008-12-08 2011-09-14 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
EP2499137A1 (en) 2009-11-13 2012-09-19 Helsinn Healthcare S.A. Palonosetron metabolites
ES2494015T3 (es) 2009-11-18 2014-09-12 Helsinn Healthcare Sa Composiciones para tratar nauseas y vómitos de origen central
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
US9358228B2 (en) 2011-10-18 2016-06-07 Helsinn Healthcare Sa Therapeutic combinations of netupitant and palonosetron
CN107137374B (zh) * 2012-06-02 2020-04-07 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
RU2015144543A (ru) * 2013-03-19 2017-04-27 Галеникум Хелс С.Л. Фармацевтические композиции, содержащие активное вещество
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3087987A4 (en) * 2013-12-23 2017-08-02 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
DE3650772T2 (de) * 1985-04-27 2003-04-03 Hoffmann La Roche Derivate von Indazole-3-carboxamide und -3-carboxylsäure
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
DE122005000027I2 (de) * 1989-11-28 2006-03-16 Roche Palo Alto Llc Tricyclische Verbindungen.
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
IL159729A0 (en) 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
HN2009000785A (es) 2011-10-14
ZA200902773B (en) 2010-03-31
BRPI0718497A2 (pt) 2014-07-08
CA2666512A1 (en) 2008-05-02
KR101441459B1 (ko) 2014-09-18
IL198225A (en) 2013-03-24
ME01949B (me) 2010-08-31
HK1117769A1 (en) 2009-01-23
AU2007308378A1 (en) 2008-05-02
EP1940366A1 (en) 2008-07-09
ES2325339T3 (es) 2009-09-01
BRPI0718497B1 (pt) 2024-02-06
US20080152704A1 (en) 2008-06-26
WO2008049552A1 (en) 2008-05-02
IL198225A0 (en) 2009-12-24
UA97653C2 (ru) 2012-03-12
CL2007003055A1 (es) 2008-03-24
PL1940366T3 (pl) 2009-09-30
CA2666512C (en) 2014-05-27
SI1940366T1 (sl) 2009-08-31
KR20090073234A (ko) 2009-07-02
AU2007308378B2 (en) 2013-02-21
TW200827355A (en) 2008-07-01
US20170035748A1 (en) 2017-02-09
CO6160289A2 (es) 2010-05-20
GT200900096A (es) 2011-08-29
PT1940366E (pt) 2009-06-17
NZ576237A (en) 2011-12-22
HRP20090341T1 (en) 2009-07-31
RS50842B (sr) 2010-08-31
DE602007000856D1 (de) 2009-05-20
JP2009507933A (ja) 2009-02-26
NO20091945L (no) 2009-05-25
CY1109914T1 (el) 2014-09-10
EA016455B1 (ru) 2012-05-30
ATE427742T1 (de) 2009-04-15
EP1940366B1 (en) 2009-04-08
CR10728A (es) 2009-07-23
NO342353B1 (no) 2018-05-07
MX2009004461A (es) 2009-09-16
TWI367212B (en) 2012-07-01
EP1940366B9 (en) 2009-12-02
CN101573106B (zh) 2013-07-24
DK1940366T3 (da) 2009-06-29
EA200970396A1 (ru) 2009-10-30
CN101573106A (zh) 2009-11-04
JP5144527B2 (ja) 2013-02-13
AR063362A1 (es) 2009-01-21

Similar Documents

Publication Publication Date Title
HN2009000785A (es) Formas de dosificacion de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
EA201000784A1 (ru) Антагонисты пути hedgehog и их терапевтические применения
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
EA201591166A1 (ru) Ингибиторы аутотаксина
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
EA201590165A1 (ru) Сдерживающие злоупотребление фармацевтические композиции для контролируемого высвобождения
CL2014000956A1 (es) Compuestos derivados de (4-fenilimidazol-2-il)etilamina, como moduladores de canal de sodio; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
EA201300465A1 (ru) Устойчивые оральные фармацевтические дозированные формы, содержащие опиоидный анальгетик
EA201590590A1 (ru) Модуляторы рецептора андрогенов и их применение
UY32776A (es) Compuestos de imidazopirazinas sustituidas para el tratamiento de enfermedades parasitarias,composiciones farmacéuticas que los contienen y aplicación.
UY33017A (es) Tratamiento para trastornos gastrointestinales
EA201991029A1 (ru) Ингибиторы magl
BR112014017673A8 (pt) Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
UY35073A (es) Derivados de pirrolidinona como moduladores de GPR119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados.
EA201590932A1 (ru) Композиции, содержащие вортиоксетин и донепезил
CL2013003125A1 (es) Compuestos derivados de isoxazolinas inhibidores mps; composicion farmaceutica que los comprende; kit farmaceutico; y uso en el tratamiento de una enfermedad tales como osteoartritis, artritis reumatoide, artritis juvenil, artritis psoriasica, lupus eritematoso sistemico, entre otras.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
EA200970816A1 (ru) Новая лекарственная форма
CL2016003131A1 (es) Composiciones de omega-3, formas de dosis, y métodos de uso
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин